Cover Image
市場調查報告書

大腸癌診斷檢驗的全球市場:醫療設備的開發平台評估

Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

出版商 GlobalData 商品編碼 366599
出版日期 內容資訊 英文 288 Pages
訂單完成後即時交付
價格
Back to Top
大腸癌診斷檢驗的全球市場:醫療設備的開發平台評估 Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
出版日期: 2016年08月06日 內容資訊: 英文 288 Pages
簡介

本報告提供全球大腸癌診斷檢驗相關產品市場上的主要開發中產品及其臨床實驗的進展調查,再彙整產品功能·特性比較分析 (臨床實驗的各進展階段) ,與主要企業簡介及代表性產品,近來的市場動靜 (業績報告·資本交易趨勢等) 資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 大腸癌診斷檢驗概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 開發中產品:現在進行中的臨床實驗

第4章 臨床實驗中的開發中產品:各企業

  • 大腸癌診斷檢驗的企業:各臨床實驗階段的開發中產品
  • 大腸癌診斷檢驗:各臨床實驗階段的開發中產品

第5章 大腸癌診斷檢驗市場:企業·產品概要 (全119公司份)

  • A2K Technologies
  • Abbott Diagnostics
  • Abcodia Ltd.
  • Acobiom
  • Advanced Marker Discovery, S.L.
  • Advpharma Inc.
  • Ambergen, Inc.
  • Ambrilia Biopharma Inc.
  • Arizona State University
  • ArtemixRx
  • Asuragen, Inc.
  • Bio Mark Ltd
  • Biocartis SA
  • Biodesix Inc.
  • BioMarCare Technologies Ltd.
  • BioMark Diagnostics Inc.
  • BioMarker Strategies, LLC
  • bioMerieux S.A.
  • Biomoda, Inc. (Inactive)
  • Biosceptre (Aust) Pty Ltd
  • BioSystems International
  • Biotechnostics GmbH
  • BioTime, Inc.
  • Biotron Limited
  • Castle Biosciences Incorporated
  • Cellmid Limited
  • Ceres Nanosciences, Inc.
  • Cernostics Inc.
  • China Sky One Medical, Inc.
  • Chronix Biomedical, Inc.
  • Cleveland Diagnostics Inc.
  • ColoPrev
  • Columbia University
  • Courtagen Life Sciences, Inc.
  • CS-Keys, Inc.
  • Di.V.A.L Toscana srl
  • Diadexus Inc
  • DiagnoCure Inc.
  • Diaxonhit S.A.
  • EDP Biotech Corporation
  • Epigenomics AG
  • Eventus Diagnostics, Inc.
  • Exact Sciences Corporation
  • Exiqon A/S
  • Exosomics Siena SpA
  • Fina Biotech
  • GenomicTree, Inc.
  • Ghent University
  • GlycoZym
  • Health Discovery Corporation
  • Human Metabolome Technologies, Inc.
  • Ikonisys, Inc.
  • InterGenetics Incorporated
  • IV Diagnostics, Inc.
  • John Hopkins University
  • Lab21 Limited
  • Laboratorios Alpha San Ignacio Pharma S.L.
  • Lightsphere Diagnostics
  • LX Diagnostics
  • MabCure Inc.
  • Matrix-Bio, Inc.
  • Max-Delbruck-Centrum fur Molekulare Medizin (MDC)
  • MDNA Life Sciences, Inc.
  • MDxHealth SA
  • Merrimack Pharmaceuticals, Inc.
  • Metabiomics Corporation
  • Metabolomic Technologies Inc.
  • Metabolon, Inc.
  • MetaStat, Inc.
  • Milagen, Inc.
  • Miraculins Inc.
  • Mode Dx Ltd.
  • Moscow Institute of Physics and Technology
  • Myriad Genetics, Inc.
  • Nanosphere, Inc.
  • NetScientific Plc
  • Norda ASA
  • Novel Bio-spectrum Technologies, Inc.
  • Nuclea Biotechnologies Inc.
  • Nuvera Biosciences, Inc.
  • Oncimmune (USA) LLC
  • OncoVista Innovative Therapies, Inc.
  • On-Q-ity, Inc. (Inactive)
  • Origin Sciences Limited
  • Orion Genomics LLC
  • OTraces Inc.
  • Oxford Cancer Biomarkers
  • Oxford Gene Technology Limited
  • Panacea Pharmaceuticals, Inc.
  • PleX Diagnostics
  • Precision Biologics, Inc.
  • Prediction Sciences
  • Protagen AG
  • Rabin Medical Center
  • Rosetta Genomics Ltd
  • Scienion AG
  • Seegene, Inc.
  • Shuwen Biotech Co. Ltd.
  • Siamab Therapeutics, Inc.
  • Skuldtech France
  • Sysmex
  • Tel Aviv University
  • The Chinese University of Hong Kong
  • The Walter and Eliza Hall Institute of Medical Research
  • TheraDiag SA
  • Theranostics Health, Inc.
  • Todos Medical Company Overview
  • Universal Diagnostics, S. L.
  • Universite De Lyon
  • University of Alabama at Birmingham
  • University of Illinois at Chicago
  • University of Texas at Austin
  • US Biomarkers, Inc.
  • Vanderbilt University
  • Vermillion, Inc.
  • Viomics Inc.
  • Vitatex Inc.
  • VolitionRX Ltd.
  • XEPTAGEN SpA

第6章 大腸癌診斷檢驗市場市場:目前的趨勢 (全99件)

第7章 附錄

圖表一覽

目錄
Product Code: GDME0218EPD

GlobalData's Medical Devices sector report, "Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Colorectal Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Colorectal Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Colorectal Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Colorectal Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Colorectal Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Colorectal Cancer Diagnostic Tests Overview

3. Products under Development

  • 3.1. Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development
  • 3.2. Colorectal Cancer Diagnostic Tests - Pipeline Products by Territory
  • 3.3. Colorectal Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
  • 3.4. Colorectal Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
  • 3.5. Colorectal Cancer - Ongoing Clinical Trials

4. Colorectal Cancer Diagnostic Tests - Pipeline Products under Development by Companies

  • 4.1. Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development
  • 4.2. Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development

5. Colorectal Cancer Diagnostic Tests Companies and Product Overview

  • 5.1. A2K Technologies Company Overview
  • 5.2. Abbott Diagnostics Company Overview
  • 5.3. Abcodia Ltd. Company Overview
  • 5.4. Acobiom Company Overview
  • 5.5. Advanced Marker Discovery, S.L. Company Overview
  • 5.6. Advpharma Inc. Company Overview
  • 5.7. Ambergen, Inc. Company Overview
  • 5.8. Ambrilia Biopharma Inc. Company Overview
  • 5.9. Arizona State University Company Overview
  • 5.10. ArtemixRx Company Overview
  • 5.11. Asuragen, Inc. Company Overview
  • 5.12. Bio Mark Ltd Company Overview
  • 5.13. Biocartis SA Company Overview
  • 5.14. Biodesix Inc. Company Overview
  • 5.15. BioMarCare Technologies Ltd. Company Overview
  • 5.16. BioMark Diagnostics Inc. Company Overview
  • 5.17. BioMarker Strategies, LLC Company Overview
  • 5.18. bioMerieux S.A. Company Overview
  • 5.19. Biomoda, Inc. (Inactive) Company Overview
  • 5.20. Biosceptre (Aust) Pty Ltd Company Overview
  • 5.21. BioSystems International Company Overview
  • 5.22. Biotechnostics GmbH Company Overview
  • 5.23. BioTime, Inc. Company Overview
  • 5.24. Biotron Limited Company Overview
  • 5.25. Castle Biosciences Incorporated Company Overview
  • 5.26. Cellmid Limited Company Overview
  • 5.27. Ceres Nanosciences, Inc. Company Overview
  • 5.28. Cernostics Inc. Company Overview
  • 5.29. China Sky One Medical, Inc. Company Overview
  • 5.30. Chronix Biomedical, Inc. Company Overview
  • 5.31. Cleveland Diagnostics Inc. Company Overview
  • 5.32. ColoPrev Company Overview
  • 5.33. Columbia University Company Overview
  • 5.34. Courtagen Life Sciences, Inc. Company Overview
  • 5.35. CS-Keys, Inc. Company Overview
  • 5.36. Di.V.A.L Toscana srl Company Overview
  • 5.37. Diadexus Inc Company Overview
  • 5.38. DiagnoCure Inc. Company Overview
  • 5.39. Diaxonhit S.A. Company Overview
  • 5.40. EDP Biotech Corporation Company Overview
  • 5.41. Epigenomics AG Company Overview
  • 5.42. Eventus Diagnostics, Inc. Company Overview
  • 5.43. Exact Sciences Corporation Company Overview
  • 5.44. Exiqon A/S Company Overview
  • 5.45. Exosomics Siena SpA Company Overview
  • 5.46. Fina Biotech Company Overview
  • 5.47. GenomicTree, Inc. Company Overview
  • 5.48. Ghent University Company Overview
  • 5.49. GlycoZym Company Overview
  • 5.50. Health Discovery Corporation Company Overview
  • 5.51. Human Metabolome Technologies, Inc. Company Overview
  • 5.52. Ikonisys, Inc. Company Overview
  • 5.53. InterGenetics Incorporated Company Overview
  • 5.54. IV Diagnostics, Inc. Company Overview
  • 5.55. John Hopkins University Company Overview
  • 5.56. Lab21 Limited Company Overview
  • 5.57. Laboratorios Alpha San Ignacio Pharma S.L. Company Overview
  • 5.58. Lightsphere Diagnostics Company Overview
  • 5.59. LX Diagnostics Company Overview
  • 5.60. MabCure Inc. Company Overview
  • 5.61. Matrix-Bio, Inc. Company Overview
  • 5.62. Max-Delbruck-Centrum fur Molekulare Medizin (MDC) Company Overview
  • 5.63. MDNA Life Sciences, Inc. Company Overview
  • 5.64. MDxHealth SA Company Overview
  • 5.65. Merrimack Pharmaceuticals, Inc. Company Overview
  • 5.66. Metabiomics Corporation Company Overview
  • 5.67. Metabolomic Technologies Inc. Company Overview
  • 5.68. Metabolon, Inc. Company Overview
  • 5.69. MetaStat, Inc. Company Overview
  • 5.70. Milagen, Inc. Company Overview
  • 5.71. Miraculins Inc. Company Overview
  • 5.72. Mode Dx Ltd. Company Overview
  • 5.73. Moscow Institute of Physics and Technology Company Overview
  • 5.74. Myriad Genetics, Inc. Company Overview
  • 5.75. Nanosphere, Inc. Company Overview
  • 5.76. NetScientific Plc Company Overview
  • 5.77. Norda ASA Company Overview
  • 5.78. Novel Bio-spectrum Technologies, Inc. Company Overview
  • 5.79. Nuclea Biotechnologies Inc. Company Overview
  • 5.80. Nuvera Biosciences, Inc. Company Overview
  • 5.81. Oncimmune (USA) LLC Company Overview
  • 5.82. OncoVista Innovative Therapies, Inc. Company Overview
  • 5.83. On-Q-ity, Inc. (Inactive) Company Overview
  • 5.84. Origin Sciences Limited Company Overview
  • 5.85. Orion Genomics LLC Company Overview
  • 5.86. OTraces Inc. Company Overview
  • 5.87. Oxford Cancer Biomarkers Company Overview
  • 5.88. Oxford Gene Technology Limited Company Overview
  • 5.89. Panacea Pharmaceuticals, Inc. Company Overview
  • 5.90. PleX Diagnostics Company Overview
  • 5.91. Precision Biologics, Inc. Company Overview
  • 5.92. Prediction Sciences Company Overview
  • 5.93. Protagen AG Company Overview
  • 5.94. Rabin Medical Center Company Overview
  • 5.95. Rosetta Genomics Ltd Company Overview
  • 5.96. Scienion AG Company Overview
  • 5.97. Seegene, Inc. Company Overview
  • 5.98. Shuwen Biotech Co. Ltd. Company Overview
  • 5.99. Siamab Therapeutics, Inc. Company Overview
  • 5.100. Skuldtech France Company Overview
  • 5.101. Sysmex Corporation Company Overview
  • 5.102. Tel Aviv University Company Overview
  • 5.103. The Chinese University of Hong Kong Company Overview
  • 5.104. The Walter and Eliza Hall Institute of Medical Research Company Overview
  • 5.105. TheraDiag SA Company Overview
  • 5.106. Theranostics Health, Inc. Company Overview
  • 5.107. Todos Medical Company Overview
  • 5.108. Universal Diagnostics, S. L. Company Overview
  • 5.109. Universite De Lyon Company Overview
  • 5.110. University of Alabama at Birmingham Company Overview
  • 5.111. University of Illinois at Chicago Company Overview
  • 5.112. University of Texas at Austin Company Overview
  • 5.113. US Biomarkers, Inc. Company Overview
  • 5.114. Vanderbilt University Company Overview
  • 5.115. Vermillion, Inc. Company Overview
  • 5.116. Viomics Inc. Company Overview
  • 5.117. Vitatex Inc. Company Overview
  • 5.118. VolitionRX Ltd. Company Overview
  • 5.119. XEPTAGEN SpA Company Overview

6. Colorectal Cancer Diagnostic Tests - Recent Developments

  • 6.1. Aug 02, 2016: Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance
  • 6.2. Jul 28, 2016: Exact Sciences Prices Public Offering of Shares for USD132 Million
  • 6.3. Jul 28, 2016: Merck Enters into Co-Development Agreement with Amoy Diagnostics
  • 6.4. Jul 28, 2016: Illumina Names Philip W. Schiller to its Board of Directors
  • 6.5. Jul 28, 2016: PRA Health Sciences Reports Second Quarter 2016 Results
  • 6.6. Jul 28, 2016: SCIENION and Applied Microarrays announce a strategic partnership to deliver next generation medical devices
  • 6.7. Jul 27, 2016: VolitionRx Granted Fourth U.S. Patent
  • 6.8. Jul 26, 2016: Exact Sciences Completes 54,000 Cologuard Tests during the Second Quarter
  • 6.9. Jul 26, 2016: NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016
  • 6.10. Jul 26, 2016: Illumina Reports Financial Results for Second Quarter of Fiscal Year 2016
  • 6.11. Jul 20, 2016: Protagen Appoints Bernhard Kirschbaum as New Chairman and Oliver Schacht as New Board Member
  • 6.12. Jul 19, 2016: SpectraScience Appoints AMG as Exclusive Distributor in Middle East
  • 6.13. Jul 18, 2016: bioMerieux - Second-Quarter 2016 Business Review
  • 6.14. Jul 13, 2016: NCQA Proposes Inclusion of Cologuard in 2017 HEDIS Quality Measures
  • 6.15. Jul 13, 2016: Biodesix Raises USD6 Million in Venture Financing
  • 6.16. Jul 13, 2016: Nasdaq Copenhagen accepts Exiqon request for delisting and cancellation from trading of the Exiqon shares
  • 6.17. Jul 11, 2016: THERADIAG Appoints Vincent Fert to Theradiag's Board of Directors
  • 6.18. Jul 08, 2016: Researchers Design Blood Test To Determine Colon Cancer Treatment
  • 6.19. Jul 07, 2016: IntegraGen reports strong revenue growth during first half of 2016
  • 6.20. Jul 07, 2016: Enzo Biochem's Life Sciences Unit Reaches $21 Million Patent Infringement Settlement in Delaware With Illumina
  • 6.21. Jul 06, 2016: Walter and Eliza Hall Research Institute Scientists Announces An end to 'futile' chemotherapy in sight
  • 6.22. Jul 05, 2016: Theradiag: Very strong revenue growth in the first half of 2016: +36%
  • 6.23. Jul 04, 2016: Exiqon - Nomination of candidates for the supervisory board
  • 6.24. Jun 30, 2016: Supervisory Board of Epigenomics appoints Gregory Hamilton as Chief Executive Officer (CEO)
  • 6.25. Jun 30, 2016: Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance
  • 6.26. Jun 27, 2016: ADL Launches Revolutionary Urine-Based Diagnostic Test To Detect Precursor To Deadly Colorectal Cancer
  • 6.27. Jun 24, 2016: VolitionRx Appoints Dr. Edward Futcher to Board of Directors
  • 6.28. Jun 23, 2016: Oncimmune Appoints Julian Hirst as Non-Executive Director
  • 6.29. Jun 15, 2016: Exact Sciences' Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations
  • 6.30. Jun 15, 2016: GeneNews Announces Filing of Q1-2016 Financial Results
  • 6.31. Jun 10, 2016: Netscientific Confirms Start Date for Ian Postlethwaite as CFO
  • 6.32. Jun 10, 2016: Diadexus to File Chapter 7
  • 6.33. Jun 09, 2016: Liquid biopsy test - GATCLIQUID ONCOTARGET - expanded to cover blood cancers such as acute myeloid leukaemia
  • 6.34. Jun 03, 2016: Exact Sciences Appoints Jeff Elliott to Lead Business Development & Strategy
  • 6.35. Jun 02, 2016: Illumina Appoints Paula Dowdy Senior Vice President and General Manager of Commercial Operations for Europe, the Middle East and Africa
  • 6.36. May 27, 2016: GeneNews Announces Full Year 2015 Financial Results
  • 6.37. May 26, 2016: MetaStat Raises USD0.5 Million in Venture Financing
  • 6.38. May 26, 2016: Cellmid provides update on Japanese sale
  • 6.39. May 23, 2016: Epigenomics Announces 2016 First Quarter Financial Results and Reports on Operational Highlights
  • 6.40. May 19, 2016: VolitionRx to Present Data Demonstrating Accuracy of NuQ Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting
  • 6.41. May 19, 2016: GeneNews Announces a Further Extension of the TSX's Remedial Review Process
  • 6.42. May 17, 2016: Cancer Prevention and Research Institute of Texas Marks Progress at the Halfway Point of its Funding
  • 6.43. May 16, 2016: Nanosphere Announces First Quarter Results
  • 6.44. May 16, 2016: Vermillion Reports First Quarter 2016 Results
  • 6.45. May 16, 2016: Vermillion Reports Fourth Quarter and Full Year 2015 Results
  • 6.46. May 13, 2016: VolitionRx Announces First Quarter 2016 Financial Results and Business Update
  • 6.47. May 10, 2016: BioTime Reports First Quarter Results and Recent Corporate Accomplishments
  • 6.48. May 09, 2016: Castle Biosciences Announces the Appointment of Bernhard E. Spiess as Chief Operating Officer
  • 6.49. May 09, 2016: Significant Scientific Appointment for Cellmid Advisory Board Chair
  • 6.50. May 04, 2016: Atlantic Diagnostic Labs Enters into Licensing Agreement with Metabolomic Technologies
  • 6.51. May 04, 2016: Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results
  • 6.52. May 03, 2016: Exact Sciences Completes 40,000 Cologuard Tests during First Quarter 2016
  • 6.53. May 02, 2016: China FDA names Epigenomics' blood-based Septin9 colorectal cancer test a most innovative medical product for 2015
  • 6.54. Apr 27, 2016: PRA Health Sciences Reports First Quarter 2016 Results and Updates 2016 Guidance
  • 6.55. Apr 18, 2016: LifeLabs Announces Extended Hours of Service in St. Thomas
  • 6.56. Apr 07, 2016: VolitionRx Announces CE Mark for NuQ T003 Blood Assay for Detection of Colorectal Cancer
  • 6.57. Apr 07, 2016: VolitionRx Announces CE Mark for NuQ V001 for Detection of Colorectal Cancer
  • 6.58. Mar 23, 2016: Clinical Genomics Technologies Raises USD11.4 Million in Series A Financing Round
  • 6.59. Mar 15, 2016: Theradiag presents at JFHOD the results of a microRNA signature predicting a patient's therapeutic response in locally advanced rectal cancer
  • 6.60. Mar 07, 2016: Institute for Quality Management in Healthcare Assessment and Accreditation
  • 6.61. Feb 26, 2016: Online video and print article present ColoMarker study results by BF Overholt MD
  • 6.62. Feb 25, 2016: Anthem BCBS Georgia and Virginia Contracted to Cover Cologuard as In-Network Service
  • 6.63. Feb 24, 2016: PRA Health Sciences Reports Fourth Quarter and Full Year 2015 Results and Provides 2016 Guidance
  • 6.64. Feb 23, 2016: Modeling Data Supports Cologuard Use Every Three Years
  • 6.65. Feb 22, 2016: New Canadian recommendation against colonoscopy for routine screening of colorectal cancer
  • 6.66. Feb 19, 2016: Routine Annual Screening for Colorectal Cancer Not Achieved by Fecal Blood Tests
  • 6.67. Feb 17, 2016: VolitionRx Demonstrates 75% Accuracy in Detecting Highest-Risk Pre-Cancerous Colorectal Adenomas with NuQ Blood Test
  • 6.68. Feb 11, 2016: Targeted Diagnostics Raises USD0.7 Million Financing
  • 6.69. Feb 10, 2016: Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results
  • 6.70. Jan 21, 2016: Clinical Genomics to Present Data Supporting Utility of 2-Gene Blood Test for Colorectal Cancer Recurrence at ASCO GI
  • 6.71. Jan 20, 2016: Biomarker predicts which stage II colon cancer patients may benefit from chemotherapy
  • 6.72. Jan 20, 2016: New Biomarker Identifies Colon Cancer Patients Who May Benefit from Chemotherapy
  • 6.73. Jan 11, 2016: Exact Sciences Announces Contract with Anthem BlueCross of California
  • 6.74. Jan 11, 2016: New Modeling Supports Using Cologuard Every Three Years
  • 6.75. Dec 02, 2015: CMS Corrects 2016 Reimbursement Rate for Cologuard
  • 6.76. Dec 02, 2015: Cynvenio Biosystems Enters into Agreement with University of Southern Denmark
  • 6.77. Dec 01, 2015: Sysmex Establishes New Subsidiary in Ghana - Reinforcing the Company's Business Foundation in the Markets of West and Central Africa
  • 6.78. Nov 30, 2015: med fusion Expands Molecular Diagnostic Test Menu
  • 6.79. Nov 24, 2015: Vela Diagnostics Enters into Agreement with Gustave Roussy Institute of Oncology
  • 6.80. Nov 17, 2015: PRA Health Sciences Expands Operations in Singapore
  • 6.81. Nov 09, 2015: Colorectal screening project to start in Russia with Biohit Oyj's ColonView test
  • 6.82. Nov 03, 2015: Genomic Health Reports Highest Test Growth in Two Years in Announcement of Third Quarter 2015 Financial Results
  • 6.83. Nov 02, 2015: PRA Health Sciences Reports Third Quarter 2015 Results And Provides Updated 2015 Guidance
  • 6.84. Oct 30, 2015: Stool DNA test accurate in screening for colorectal cancer in Alaska Native people
  • 6.85. Oct 28, 2015: New Study Bolsters Cologuard's Performance in Detecting Colorectal Cancer and Ability to Improve Access to Screening
  • 6.86. Oct 19, 2015: Stool DNA Screening Technology to be Featured at ACG 2015
  • 6.87. Oct 13, 2015: UCLA Health Implements Tumor DNA Profiling using GenomOncology's GO Clinical Workbench
  • 6.88. Oct 05, 2015: Cologuard Included as Alternative Screening Test under Draft USPSTF Guidelines
  • 6.89. Sep 28, 2015: CMS Issues Preliminary Determination Maintaining Cologuard Reimbursement Rate
  • 6.90. Sep 22, 2015: VolitionRx Announces CE Mark For NuQ Blood Assay For Detection Of Colorectal Cancer
  • 6.91. Sep 15, 2015: Sysmex to Expand U.S. Reagent Factory - Aiming to Meet Growing Demand in the Americas
  • 6.92. Sep 09, 2015: VolitionRx Demonstrates NuQ Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial
  • 6.93. Sep 08, 2015: Exact Sciences Announces Blue Cross Blue Shield of Rhode Island to Cover Cologuard
  • 6.94. Sep 08, 2015: Cynvenio Biosystems Receives Accreditation From College of American Pathologists
  • 6.95. Aug 31, 2015: Published Trial Results Indicate High Sensitivity and Reproducibility of Early Colon Cancer Detection by ColoMarker Blood Test
  • 6.96. Aug 26, 2015: Exact Sciences Highlights CMS Advisory Panel's Unanimous Vote to Maintain Medicare Reimbursement Rate for Cologuard
  • 6.97. Aug 24, 2015: New Blood Test for Colon Cancer Improves Colonoscopy Screening Results
  • 6.98. Aug 19, 2015: Exact Sciences Wins Wisconsin Innovation Award
  • 6.99. Aug 12, 2015: Chemimage Receives NIH Grant To Develop Blood Test For Early Detection Of Colorectal Cancer

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development
  • Table 2: Colorectal Cancer Diagnostic Tests - Pipeline Products by Territory
  • Table 3: Colorectal Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
  • Table 4: Colorectal Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
  • Table 5 Colorectal Cancer Diagnostic Tests - Ongoing Clinical Trials
  • Table 6: Colorectal Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development
  • Table 7: Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development
  • Table 8: A2K Technologies Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: Colospec - Product Status
  • Table 10: Colospec - Product Description
  • Table 11: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: RealTime mS9 Colorectal Cancer Test - Product Status
  • Table 13: RealTime mS9 Colorectal Cancer Test - Product Description
  • Table 14: Abcodia Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 15: Diagnostic Assay - Colorectal Cancer - Product Status
  • Table 16: Diagnostic Assay - Colorectal Cancer - Product Description
  • Table 17: Acobiom Pipeline Products & Ongoing Clinical Trials Overview
  • Table 18: Diagnostic Assay - Colon Cancer - Product Status
  • Table 19: Diagnostic Assay - Colon Cancer - Product Description
  • Table 20: Advanced Marker Discovery, S.L. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 21: Screening Test - Colon Cancer - Product Status
  • Table 22: Screening Test - Colon Cancer - Product Description
  • Table 23: Advpharma Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 24: Molecular Diagnostic Biomarker - Colorectal Cancer - Product Status
  • Table 25: Molecular Diagnostic Biomarker - Colorectal Cancer - Product Description
  • Table 26: Ambergen, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 27: Veracode - Colorectal Cancer - Product Status
  • Table 28: Veracode - Colorectal Cancer - Product Description
  • Table 29: Ambrilia Biopharma Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 30: Colopath/ColorectAlert - Product Status
  • Table 31: Colopath/ColorectAlert - Product Description
  • Table 32: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 33: Biomarker Test - Colorectal Cancer - Product Status
  • Table 34: Biomarker Test - Colorectal Cancer - Product Description
  • Table 35: ArtemixRx Pipeline Products & Ongoing Clinical Trials Overview
  • Table 36: ArtemixRx Prognostic Test - Colon Cancer - Product Status
  • Table 37: ArtemixRx Prognostic Test - Colon Cancer - Product Description
  • Table 38: Asuragen, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 39: Molecular Diagnostic Assay - Colon Cancer - Product Status
  • Table 40: Molecular Diagnostic Assay - Colon Cancer - Product Description
  • Table 41: Bio Mark Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 42: Diagnostic Test - Colorectal Adenoma - Product Status
  • Table 43: Diagnostic Test - Colorectal Adenoma - Product Description
  • Table 44: Biocartis SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 45: MSI-Biomarker Diagnostic Test - Colorectal Cancer - Product Status
  • Table 46: MSI-Biomarker Diagnostic Test - Colorectal Cancer - Product Description
  • Table 47: Biodesix Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 48: VeriStrat - Colorectal Cancer - Product Status
  • Table 49: VeriStrat - Colorectal Cancer - Product Description
  • Table 50: BioMarCare Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 51: Colon MarCarePlex - Product Status
  • Table 52: Colon MarCarePlex - Product Description
  • Table 53: mCRC-Strat - Product Status
  • Table 54: mCRC-Strat - Product Description
  • Table 55: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 56: Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Status
  • Table 57: Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Description
  • Table 58: BioMarker Strategies, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 59: Ex Vivo Biomarker Test - Colon Cancer - Product Status
  • Table 60: Ex Vivo Biomarker Test - Colon Cancer - Product Description
  • Table 61: bioMerieux S.A. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 62: Diagnostic Test - Colorectal Cancer - Product Status
  • Table 63: Diagnostic Test - Colorectal Cancer - Product Description
  • Table 64: Biomoda, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 65: CyPath Diagnostic Assay - Colorectal Cancer - Product Status
  • Table 66: CyPath Diagnostic Assay - Colorectal Cancer - Product Description
  • Table 67: Biosceptre (Aust) Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 68: Colorectal Cancer IHC Diagnostic Test - Product Status
  • Table 69: Colorectal Cancer IHC Diagnostic Test - Product Description
  • Table 70: BioSystems International Pipeline Products & Ongoing Clinical Trials Overview
  • Table 71: Diagnostic Test - Colon Cancer - Product Status
  • Table 72: Diagnostic Test - Colon Cancer - Product Description
  • Table 73: Biotechnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 74: Diagnostic Test - Colorectal Cancer - Product Status
  • Table 75: Diagnostic Test - Colorectal Cancer - Product Description
  • Table 76: BioTime, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 77: PanC-Dx - Colon Cancer - Product Status
  • Table 78: PanC-Dx - Colon Cancer - Product Description
  • Table 79: Biotron Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 80: C-Test - Colorectal Cancer - Product Status
  • Table 81: C-Test - Colorectal Cancer - Product Description
  • Table 82: Castle Biosciences Incorporated Pipeline Products & Ongoing Clinical Trials Overview
  • Table 83: DecisionDx- Rectal Cancer - Product Status
  • Table 84: DecisionDx- Rectal Cancer - Product Description
  • Table 85: Cellmid Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 86: MK-ELISA Assay - Colorectal Cancer - Product Status
  • Table 87: MK-ELISA Assay - Colorectal Cancer - Product Description
  • Table 88: MK-ELISA Assay - Metastatic Colorectal Cancer - Product Status
  • Table 89: MK-ELISA Assay - Metastatic Colorectal Cancer - Product Description
  • Table 90: Ceres Nanosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 91: Nanotrap Colon Cancer Biomarker Test - Product Status
  • Table 92: Nanotrap Colon Cancer Biomarker Test - Product Description
  • Table 93: Cernostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 94: TissueCypher Colon Cancer Test - Product Status
  • Table 95: TissueCypher Colon Cancer Test - Product Description
  • Table 96: China Sky One Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 97: Diagnostic Kit - Rectum Cancer - Product Status
  • Table 98: Diagnostic Kit - Rectum Cancer - Product Description
  • Table 99: Chronix Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 100: Companion Diagnostic Test - Colorectal Cancer - Product Status
  • Table 101: Companion Diagnostic Test - Colorectal Cancer - Product Description
  • Table 102: Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 103: Blood-Based Diagnostic Test - Colon Cancer - Product Status
  • Table 104: Blood-Based Diagnostic Test - Colon Cancer - Product Description
  • Table 105: ColoPrev Pipeline Products & Ongoing Clinical Trials Overview
  • Table 106: Blood-Based Diagnostic Test - Colorectal Cancer - Product Status
  • Table 107: Blood-Based Diagnostic Test - Colorectal Cancer - Product Description
  • Table 108: Columbia University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 109: IGFBP-3 Diagnostic Test - Product Status
  • Table 110: IGFBP-3 Diagnostic Test - Product Description
  • Table 111: Courtagen Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 112: Colorectal Cancer Diagnostic Panel - Product Status
  • Table 113: Colorectal Cancer Diagnostic Panel - Product Description
  • Table 114: CS-Keys, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 115: caPCNA - Colorectal Cancer - Product Status
  • Table 116: caPCNA - Colorectal Cancer - Product Description
  • Table 117: Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview
  • Table 118: NanoMabKv - Colorectal Cancer - Product Status
  • Table 119: NanoMabKv - Colorectal Cancer - Product Description
  • Table 120: Diadexus Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 121: TRAIL-R2 Assay - Product Status
  • Table 122: TRAIL-R2 Assay - Product Description
  • Table 123: DiagnoCure Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 124: Colorectal/GCC Monitoring Test - Product Status
  • Table 125: Colorectal/GCC Monitoring Test - Product Description

List of Figures

  • Figure 1: Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development
  • Figure 2: Colorectal Cancer Diagnostic Tests - Pipeline Products by Territory
  • Figure 3: Colorectal Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
  • Figure 4: Colorectal Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
  • Figure 5: Colorectal Cancer Diagnostic Tests - Ongoing Clinical Trials
Back to Top